GSA Capital Partners LLP Purchases 106,167 Shares of 10x Genomics $TXG

GSA Capital Partners LLP raised its holdings in shares of 10x Genomics (NASDAQ:TXG) by 708.9% during the third quarter, Holdings Channel.com reports. The fund owned 121,144 shares of the company’s stock after buying an additional 106,167 shares during the period. GSA Capital Partners LLP’s holdings in 10x Genomics were worth $1,416,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in TXG. Vanguard Group Inc. grew its position in shares of 10x Genomics by 6.7% during the third quarter. Vanguard Group Inc. now owns 13,274,332 shares of the company’s stock worth $155,177,000 after purchasing an additional 834,272 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in 10x Genomics by 777.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,073,865 shares of the company’s stock worth $12,553,000 after purchasing an additional 951,495 shares during the period. Abich Financial Wealth Management LLC bought a new position in 10x Genomics in the 3rd quarter worth approximately $56,000. Cibc World Market Inc. grew its holdings in 10x Genomics by 60.5% during the 3rd quarter. Cibc World Market Inc. now owns 62,464 shares of the company’s stock valued at $730,000 after buying an additional 23,543 shares in the last quarter. Finally, Stratos Wealth Partners LTD. bought a new stake in shares of 10x Genomics during the third quarter valued at approximately $153,000. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Benjamin J. Hindson sold 8,283 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $19.00, for a total value of $157,377.00. Following the sale, the insider owned 432,605 shares of the company’s stock, valued at approximately $8,219,495. This represents a 1.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Adam Taich sold 11,888 shares of 10x Genomics stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $225,872.00. Following the transaction, the chief financial officer directly owned 297,385 shares of the company’s stock, valued at approximately $5,650,315. This represents a 3.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 33,432 shares of company stock valued at $635,208. 10.03% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. UBS Group upped their target price on shares of 10x Genomics from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Bank of America set a $21.00 price objective on shares of 10x Genomics in a report on Monday, January 12th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $20.00 target price (up from $17.00) on shares of 10x Genomics in a report on Monday, December 1st. Zacks Research lowered 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Finally, Wall Street Zen cut 10x Genomics from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, 10x Genomics currently has an average rating of “Hold” and an average price target of $17.68.

10x Genomics Trading Up 2.8%

Shares of NASDAQ:TXG opened at $18.62 on Wednesday. 10x Genomics has a 12 month low of $6.78 and a 12 month high of $23.56. The company has a 50-day moving average price of $18.70 and a 200 day moving average price of $15.69. The company has a market cap of $2.36 billion, a price-to-earnings ratio of -53.20 and a beta of 2.24.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Thursday, February 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.06. 10x Genomics had a negative return on equity of 6.99% and a negative net margin of 6.77%.The company had revenue of $166.03 million for the quarter, compared to analysts’ expectations of $160.35 million. During the same period in the previous year, the firm posted ($0.40) earnings per share. The firm’s revenue for the quarter was up .6% on a year-over-year basis. As a group, equities analysts forecast that 10x Genomics will post -1.43 EPS for the current year.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.